Vivere Oncotherapies engineers cancer therapies that activate the immune system to detect and eliminate solid tumors that typically evade immune surveillance. Using a proprietary bioengineering platform created at UC Berkeley, the team designs delivery vehicles that reach tumors more efficiently and release highly selective, immune-stimulating payloads. The company’s scientific approach merges engineering, immunology, and translational expertise to crack the longstanding problem of immunologically cold tumors, which are resistant to conventional checkpoint inhibitors. With its technology, Vivere aims to bring a new generation of targeted and safer immunotherapies to patients who currently have few effective options and poor prognoses. Future plans include advancing these candidates toward clinical development and expanding the platform to additional hard-to-treat cancers. Financially, the company has secured over $10 million in new capital to fuel preclinical development and platform expansion; no other operating metrics or revenue figures were disclosed.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2026